OnKure Therapeutics Inc. (OKUR)
NASDAQ: OKUR
· Real-Time Price · USD
2.82
0.29 (11.46%)
At close: Aug 18, 2025, 2:57 PM
OnKure Therapeutics Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 643K | 655K | 594K | 466K | 497K | 485K | 334K | 43K | n/a | n/a |
Gross Profit | -643K | -655K | -594K | -466K | -497K | -485K | -334K | -43K | n/a | n/a |
Operating Income | -71.78M | -69.8M | -62.63M | -7.72M | -23.95M | -18.24M | -17.16M | -38.27M | -17.39M | -8.75M |
Interest Income | 2.01M | 1.3M | 525K | 525K | 525K | 746K | 524K | 524K | 524K | 73K |
Pretax Income | -54.81M | -68.95M | -62.56M | -8.84M | -24.35M | -18.39M | -17.54M | -36.06M | -16.86M | -8.68M |
Net Income | -54.81M | -68.95M | -62.56M | -8.84M | -24.35M | -18.39M | -17.54M | -36.06M | -16.86M | -8.68M |
Selling & General & Admin | 7.89M | 7.78M | 5.05M | -5.6M | -2.1M | -4.57M | -4.6M | 9.62M | 2.35M | 1.23M |
Research & Development | 63.89M | 62.03M | 57.58M | 13.33M | 26.05M | 22.81M | 21.77M | 28.66M | 15.04M | 7.52M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 71.78M | 69.8M | 62.63M | 7.72M | 23.95M | 18.24M | 17.16M | 38.27M | 17.39M | 8.75M |
Interest Expense | n/a | 26K | 26K | 26K | 26K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 55.46M | 69.8M | 62.63M | 7.72M | 23.95M | 18.24M | 17.16M | 38.27M | 17.39M | 8.75M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 135.09M | 13.42M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M |
Shares Outstanding (Diluted) | 135.09M | 13.42M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M |
EPS (Basic) | -5.25 | -5.17 | -4.69 | -0.66 | -1.82 | -1.37 | -1.31 | -2.7 | -1.26 | -0.65 |
EPS (Diluted) | -5.25 | -5.17 | -4.69 | -0.66 | -1.82 | -1.37 | -1.31 | -2.7 | -1.26 | -0.65 |
EBITDA | -61.18M | -58.82M | -51.71M | 996K | -41.74M | -35.81M | -34.75M | -56.3M | -16.65M | -8.62M |
EBIT | -45.43M | -59.54M | -52.37M | 522K | -42.32M | -36.39M | -35.31M | -56.42M | -16.93M | -8.75M |
Depreciation & Amortization | 575K | 723K | 662K | 474K | 576K | 583K | 560K | 126K | 283K | 128K |